Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Tokyo - Delayed Quote JPY

Nippon Shinyaku Co., Ltd. (4516.T)

Compare
3,504.00
-76.00
(-2.12%)
At close: April 4 at 3:30:00 PM GMT+9
Loading Chart for 4516.T
  • Previous Close 3,580.00
  • Open 3,580.00
  • Bid 3,503.00 x --
  • Ask 3,517.00 x --
  • Day's Range 3,471.00 - 3,584.00
  • 52 Week Range 2,694.00 - 4,475.00
  • Volume 242,400
  • Avg. Volume 243,834
  • Market Cap (intraday) 236.095B
  • Beta (5Y Monthly) -0.24
  • PE Ratio (TTM) 7.76
  • EPS (TTM) 451.32
  • Earnings Date May 8, 2025 - May 12, 2025
  • Forward Dividend & Yield 124.00 (3.54%)
  • Ex-Dividend Date Mar 28, 2025
  • 1y Target Est 4,212.50

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. Its Pharmaceuticals Business segment offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases. The company's Functional Food Business segments provides health food ingredients, preservatives, protein preparations, and sports and supplements. The company in the Strategic Partnership with Nippon Shinyaku will develop and commercialize for Mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.

www.nippon-shinyaku.co.jp

2,213

Full Time Employees

March 31

Fiscal Year Ends

Recent News: 4516.T

View More

Performance Overview: 4516.T

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

4516.T
10.78%
Nikkei 225 (^N225)
15.33%

1-Year Return

4516.T
16.52%
Nikkei 225 (^N225)
15.07%

3-Year Return

4516.T
54.73%
Nikkei 225 (^N225)
21.79%

5-Year Return

4516.T
49.04%
Nikkei 225 (^N225)
89.56%

Compare To: 4516.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4516.T

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    236.09B

  • Enterprise Value

    178.47B

  • Trailing P/E

    7.76

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.51

  • Price/Book (mrq)

    0.95

  • Enterprise Value/Revenue

    1.14

  • Enterprise Value/EBITDA

    4.22

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.38%

  • Return on Assets (ttm)

    7.88%

  • Return on Equity (ttm)

    13.13%

  • Revenue (ttm)

    156.85B

  • Net Income Avi to Common (ttm)

    30.4B

  • Diluted EPS (ttm)

    451.32

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    55.42B

  • Total Debt/Equity (mrq)

    0.99%

  • Levered Free Cash Flow (ttm)

    4.29B

Research Analysis: 4516.T

View More

Company Insights: 4516.T

Research Reports: 4516.T

View More

People Also Watch